1.0South Africa Voicehttps://southafricavoice.comSouth Africa Voicehttps://southafricavoice.com/author/southafricavoice01/rich600338<blockquote class="wp-embedded-content" data-secret="NNz1vj6HFW"><a href="https://southafricavoice.com/zenas-biopharma-announces-strategic-license-and-collaboration-agreement-with-bristol-myers-squibb-to-develop-and-commercialize-novel-bi-functional-antibody-obexelimab-in-japan-south-korea-taiwan-si/">Zenas BioPharma Announces Strategic License and Collaboration Agreement with Bristol Myers Squibb to Develop and Commercialize Novel Bi-Functional Antibody Obexelimab in Japan, South Korea, Taiwan, Singapore, Hong Kong and Australia</a></blockquote><iframe sandbox="allow-scripts" security="restricted" src="https://southafricavoice.com/zenas-biopharma-announces-strategic-license-and-collaboration-agreement-with-bristol-myers-squibb-to-develop-and-commercialize-novel-bi-functional-antibody-obexelimab-in-japan-south-korea-taiwan-si/embed/#?secret=NNz1vj6HFW" width="600" height="338" title="“Zenas BioPharma Announces Strategic License and Collaboration Agreement with Bristol Myers Squibb to Develop and Commercialize Novel Bi-Functional Antibody Obexelimab in Japan, South Korea, Taiwan, Singapore, Hong Kong and Australia” — South Africa Voice" data-secret="NNz1vj6HFW" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"></iframe><script> /*! This file is auto-generated */ !function(d,l){"use strict";l.querySelector&&d.addEventListener&&"undefined"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i<o.length;i++)o[i].style.display="none";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute("style"),"height"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):"link"===t.message&&(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document); </script> Collaboration furthers Zenas’ vision to bring innovative immunology-based medicines to patients around the world by leveraging Bristol Myers Squibb’s long-standing expertise in immune-mediated diseases Zenas will receive a $50 million up-front cash payment and an equity investment from Bristol Myers Squibb, along with additional potential milestone-based payments and royalties in the licensed territory WALTHAM, Mass., […]https://ci4.googleusercontent.com/proxy/zGy8ISIDLZ-npxfmoU9LrYWKubT81dbH-odO4nxJVEDsUXljO94pnr_TJt5fLrA5Y2UzxWeBpui6o4pAuwbfq-J8uHOf3d00DDp9i0iF5xUDm4Kubvr84S31zjAXeVAn=s0-d-e1-ft#https://www.globenewswire.com/newsroom/ti?nf=ODkxNjAyOSM1NzkxNTgwIzIyMDc3OTU=